Paris (France) and Cambridge (Massachusetts, USA), May 29, 2026 – 10:00 PM (CET) – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, hereby informs the market, further to its press release dated April 29, 2026, that the work required to finalize the 2025 annual accounts and to prepare the audit procedures is still ongoing and will not allow publication of the accounts within the previously announced timeframe.
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer